Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167:171-186.
Haftchenary S, Nelson SD Jr, Furst L, et al. Efficient routes to a diverse array of amino alcohol-derived chiral fragments. ACS Comb Sci. 2016;18(9):569-574.
Ferrara SJ, Burton JW. A short synthesis of aphanamol I in both racemic and enantiopure forms. Chem Eur J. 2016;22:11597-11600.
Steven Ferrara, Ph.D.
Steven Ferrara is a research scientist II in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, where he works under the direction of Robert Hilgraf on developing novel therapeutic strategies for use as cancer treatments through the design of potent and highly selective small molecules. Areas of interest include epigenetic and cellular metabolism targets as well as disruption of protein-protein interactions. These endeavors have resulted in the identification and selection of a clinical candidate for treatment of patients diagnosed with acute myeloid leukemia (AML).
Ferrara joined the Broad Institute as a postdoctoral research associate in 2014, after completing a similar position at Yale conducting research investigating fragment libraries and their use in drug discovery in partnership with Bayer. He undertook a six-month visiting research post in conjunction with his appointment to a research scientist I position at the Broad Institute; he moved into his current post in July 2016.
Ferrara obtained his Ph.D. in organic chemistry from the University of Oxford with Professor Jonathan Burton, investigating radical cyclization and its applications in total synthesis. He also holds a M.Chem. (Hons) from the University of Sheffield, with an industrial placement at GlaxoSmithKline.
Contact Steven Ferrara via email at email@example.com.